HONG KONG - Pharmaceutical manufacturer Huons Co. Ltd. and biopharmaceutical research and development venture Genexine Inc. inked a memorandum of understanding for a deal, under which they will combine Genexine's biobetters and rare disease pipeline with Huons' existing global commercial network.
HONG KONG – The Korea Cancer Biomarker Consortium (KCBC), a research group of 13 university hospitals in South Korea, and South Korean biotech Cbsbioscience Inc. inked a deal with medical research institutes in Italy and Japan to develop biomarkers aimed at improving the efficiency of cancer drugs.
HONG KONG – Kolon Tissuegene Inc., of Rockville, Md., has been ordered by the U.S. FDA to halt the phase III trial of its osteoarthritis cell and gene therapy, Invossa-K, as cancerous cell lines might have been used making the product.
HONG KONG – Kolon Tissuegene Inc., of Rockville, Md., has been ordered by the U.S. FDA to halt the phase III trial of its osteoarthritis cell and gene therapy, Invossa-K, as cancerous cell lines might have been used making the product.
HONG KONG – The Korean government plans to invest KRW2.93 trillion (US$2.52 billion) this year to give the biomedical and pharmaceutical industries, as well as medical technologies a boost, according to the Ministry of Science and ICT (Information & Communications Technology). The most significant investments are likely to go toward bioscience and medicine, which will account for 54% and 18% of the budget, respectively.
HONG KONG – Samsung Bioepis Co. Ltd.'s recent FDA approval to market biosimilar Eticovo (etanercept-ykro) in the U.S., marking another significant step forward for the growing South Korean drugmaker, may not bring any real benefits for almost a decade. But the U.S. nod sets the stage for Bioepis to potentially nab a significant share of the etanercept biosimilar market in the future.
HONG KONG – The Korean government plans to invest KRW2.93 trillion (US$2.52 billion) this year to give the biomedical and pharmaceutical industries, as well as medical technologies a boost, according to the Ministry of Science and ICT (Information & Communications Technology). The most significant investments are likely to go toward bioscience and medicine, which will account for 54% and 18% of the budget, respectively.
HONG KONG – SK Biopharmaceuticals Co. Ltd., a spin-off from Korean conglomerate SK Holdings Co. Ltd., inked a joint research agreement with Twoxar Inc., a U.S.-based artificial intelligence (AI)-driven biopharma, to discover and develop drugs for non-small-cell lung cancer (NSCLC).
HONG KONG – SK Biopharmaceuticals Co. Ltd., a spin-off from Korean conglomerate SK Holdings Co. Ltd., inked a joint research agreement with Twoxar Inc., a U.S.-based artificial intelligence (AI)-driven biopharma, to discover and develop drugs for non-small-cell lung cancer (NSCLC).
